Synlogic, Inc. (SYBX)
Largest Insider Buys in Sector
SYBX Stock Price History Chart
SYBX Stock Performance
About Synlogic, Inc.
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically …
Insider Activity of Synlogic, Inc.
Over the last 12 months, insiders at Synlogic, Inc. have bought $0 and sold $1,079 worth of Synlogic, Inc. stock.
On average, over the past 5 years, insiders at Synlogic, Inc. have bought $10,640 and sold $15,152 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 9,500 shares for transaction amount of $10,640 was made by JENSEN MICHAEL VANGSTED (Chief Financial Officer) on 2022‑05‑24.
List of Insider Buy and Sell Transactions, Synlogic, Inc.
| 2024-10-29 | Sale | Head of Finance | 79 0.0006% | $1.40 | $111 | -2.05% | ||
| 2024-04-02 | Sale | Chief Operating Officer | 372 0.0031% | $1.73 | $644 | -13.07% | ||
| 2024-04-02 | Sale | Head of Finance | 188 0.0016% | $1.73 | $325 | -13.07% | ||
| 2023-04-03 | Sale | See Remarks | 19,042 0.0274% | $0.58 | $10,964 | +200.86% | ||
| 2023-04-03 | Sale | Chief Operating Officer | 6,438 0.0093% | $0.58 | $3,707 | +200.86% | ||
| 2023-04-03 | Sale | Chief Financial Officer | 2,553 0.0037% | $0.58 | $1,470 | +200.86% | ||
| 2022-05-24 | Chief Financial Officer | 9,500 0.0132% | $1.12 | $10,640 | -20.36% | |||
| 2022-04-04 | Sale | See Remarks | 8,894 0.0129% | $2.45 | $21,754 | -57.73% | ||
| 2022-04-04 | Sale | Chief Operating Officer | 2,650 0.0039% | $2.45 | $6,482 | -57.73% | ||
| 2019-12-13 | director | 7,500 0.0252% | $2.74 | $20,550 | -7.98% | |||
| 2019-02-13 | Sale | Chief Scientific Officer | 5,849 0.022% | $9.75 | $57,028 | -53.61% | ||
| 2019-02-12 | Sale | Chief Scientific Officer | 3,151 0.0127% | $9.75 | $30,722 | -50.05% | ||
| 2018-10-18 | Sale | Chief Scientific Officer | 3,000 0.0132% | $9.77 | $29,296 | -16.09% | ||
| 2018-09-18 | Sale | Chief Scientific Officer | 3,000 0.0119% | $13.05 | $39,163 | -38.59% | ||
| 2018-09-05 | Sale | Chief Scientific Officer | 3,000 0.0117% | $12.55 | $37,635 | -36.76% | ||
| 2018-08-30 | Sale | Chief Scientific Officer | 1,342 0.0052% | $9.76 | $13,092 | -19.08% | ||
| 2018-08-29 | Sale | Chief Scientific Officer | 1,658 0.0067% | $9.77 | $16,198 | -15.54% | ||
| 2018-07-18 | Sale | Chief Scientific Officer | 3,000 0.0118% | $11.01 | $33,022 | -25.32% | ||
| 2018-06-20 | Sale | Chief Scientific Officer | 2,054 0.0081% | $9.78 | $20,079 | -17.00% | ||
| 2018-06-19 | Sale | Chief Scientific Officer | 946 0.0039% | $9.75 | $9,224 | -13.81% |
Insider Historical Profitability
| POWELL MICHAEL | 2974811 25.4342% | $1.42 | 1 | 0 | <0.0001% | |
| Sofinnova Venture Partners VIII, L.P. | 10 percent owner | 2974811 25.4342% | $1.42 | 1 | 0 | <0.0001% |
| BARRIS PETER J | 10 percent owner | 2971517 25.406% | $1.42 | 1 | 0 | <0.0001% |
| BARRETT M JAMES | 10 percent owner | 2971517 25.406% | $1.42 | 1 | 0 | <0.0001% |
| MOTT DAVID M | 10 percent owner | 2971517 25.406% | $1.42 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Nea Management Company Llc | $5.23M | 24.97 | 2.92M | 0% | -$3.58 | 0.02 | |
| Fidelity Investments | $412,074.00 | 1.97 | 230,209 | -10.99% | -$50,898.64 | <0.0001 | |
| The Vanguard Group | $327,574.00 | 1.56 | 183,002 | -2.88% | -$9,721.50 | <0.0001 | |
| Renaissance Technologies | $212,000.00 | 1.01 | 118,435 | +116.8% | +$114,211.68 | <0.0001 | |
| Geode Capital Management | $85,207.00 | 0.41 | 47,597 | +7.14% | +$5,682.02 | <0.0001 |